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ABSTRACT:  
The telmisartan was determined in a rat plasma using developed and validated a reversed-phase high 
performance liquid chromatographic (HPLC). The pre-treatment of the plasma sample involving liquid-liquid 
extraction using ethanol as the extracting solvent. The HPLC method validation has been shown a linear 
calibration curve over a plasma concentrations range of 0.7 to 10µg/mL with a correlation coefficient of 0.9979, 
the limit of detection and the limit of quantification were determined to be 0.025µg/ml and 0.07µg/ml, 
respectively. The precision and accuracy were in an acceptable limit. The pharmacokinetic parameters of 
telmisartan were adequately evaluated following a single oral dose (4mg/kg) in Sprague-Dawley rats. The results 
observed conclude that the developed bioanalytical HPLC method is appropriate and applicable as an analytical 
tool in the pharmacokinetic study of telmisartan. 
 




The bioanalytical method is employed for the 
quantitative estimation of drugs and their metabolites in 
biological media. It plays an important role in the 
estimation and interpretation of bioequivalence, 
pharmacokinetic and toxic kinetic studies1-3. The 
sensitivity and selectivity of bioanalytical methods are 
necessary in order to conduct preclinical and clinical 
studies successfully during the drug development 
process from the initial preclinical phase to the final 
clinical steps4,5. The chromatographic method is the most 
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Telmisartan (TEL) is chemically described as [1,1-
biphenyl]-2-carboxylic acid, 4-[(1,4-dimethyl-2-
propyl[2,6-bi-1H-benzimidazol]-1-yl)methyl]7, the 
chemical structure of TEL is shown in Fig.18. 
 
It is an angiotensin II receptor antagonist (ARB) used in 
the treatment of hypertension. The high affinity of 
angiotensin II receptor blockers (ARBs) such as 
telmisartan to the angiotensin II type 1 (AT1) receptors 
leading to inhibition of the action of angiotensin II on 
vascular smooth muscle, which in turn result in a 
reduction in arterial blood pressure9,10. The present study 
describes a simple and reproducible HPLC method using 
liquid-liquid extraction to detect the plasma 
concentrations in male Sprague-Dawley rats. The 
applicability of pharmacokinetic is also demonstrated. 
 
 
Figure 1: Chemical structure of TEL. 




MATERIALS AND METHODS: 
Chemicals and reagents: 
Telmisartan (API) and pioglitazone were purchased from 
Hangzhou Hyper Chemicals Limited, China. Potassium 
dihydrogen phosphate (KH2PO4), potassium hydroxide 
(KOH), absolute ethanol and absolute methanol were 
procured from Merck KGaA, Germany. Acetonitrile 
(HPLC grade), water (HPLC grade) was purchased from 
Fisher chemical, UK. 
 
Instrumentation and Chromatographic Conditions: 
HPLC system (HPLC 1100, Agilent) coupled with UV 
detector, autosampler and column oven, was used to 
study the concentration of TEL in rat plasma. A 
reversed-phase HPLC system was used that involves 
polar mobile phase and non-polar, hydrophobic 
stationary phase. Samples were separated using 
ZORBAX Eclipse Plus C18 4.6mm x 25cm column with 
a pore size of 5µm (Agilent Technologies) as a 
stationary phase, and the column temperature was 
ambient. The mobile phase consisted of a 50:50 (%v/v) 
mixture of acetonitrile (ACN) and 10mM phosphate 
buffer solution (pH 3.8). For all samples, the flow rate of 
the mobile phase was 1mL/min with a fixed total run 
time of 14 minutes and the injection volume of the 
sample was 10µL. The mobile phase was filtered using 
0.45µm membrane filter paper and subjected to 
degassing in an ultrasonic cleaner before running the 
HPLC analysis. The detection was done by UV detector 
with measuring wavelength at λmax (231nm), determined 
earlier by UV spectrophotometric method. The 
chromatograms data was obtained by using Lab Solution 
software (Agilent Corporation). 
 
Preparation of Standard Stock Solutions: 
Primary stock solutions of TEL and internal standard 
(IS) pioglitazone were prepared individually in 
methanol. An accurately weighed samples of 50mg of 
TEL and 50mg of pioglitazone were dissolved in 50ml 
of methanol in two separate 50ml volumetric flasks and 
sonicated for 5 minutes to produce standard stock 
solutions of 1000µg/ml. 
 
Preparation of Working Solutions: 
The working solutions of different concentrations for 
TEL were prepared from the stock solution (1000µg/ml) 
by adding an appropriate volume of mobile phase to a 
suitable volume of stock solution. They were used for 
the preparation of the calibration curve (CC) and quality 
control (QC) samples by diluting the individual 
solutions. The Working solution for pioglitazone (IS) 
was also prepared in the same way (Table 1). 
 
Preparation of Calibration Standards and Quality 
Control Samples: 
The 10µL of individual working solutions were spiked to 
80µL of the blank rat plasma to prepare calibration curve 
with the concentrations of 0.07, 0.1, 0.5, 1, 2, 5 and 10 
µg/ml for TEL in rat plasma (Table 2). Three different 
Quality control standards were prepared separately by 
spiking 10µL TEL solution to 80µL of blank rat plasma 
to achieve the final concentrations of 1.5 (Low QC), 7.5 
(Mid QC), and 15 (High QC)µg/ml of TEL in rat plasma 
(Table 3). 10µl of internal standard solution (50µg/ml) 
was added to prepare a final concentration in plasma (5 
µg/ml). All the calibration and QC samples were freshly 
prepared prior to the analysis. 
 
Table 1: working solutions used in bioanalytical method 
Type of working solution Concentration (µg/ml) 
Working solutions of TEL for (CC) 
samples 
0.7, 1, 5, 10, 20, 50, and 
100 µg/ml 
Working solutions of TEL for (QC) 
samples 
15, 75, and 150 µg/ml 
A working solution of IS 50 µg/ml 
 






+ IS (µL) 
TEL conc. in 
plasma (µg/ml) 
0.7 10 90 0.07 
1 10 90 0.1 
5 10 90 0.5 
10 10 90 1 
20 10 90 2 
50 10 90 5 
100 10 90 10 
 






+ IS (µL) 
TEL conc. in 
plasma (µg/ml) 
15 10 90 1.5 
75 10 90 7.5 
150 10 90 15 
 
The sample extraction procedure: 
Sample preparation technique used for the study plays a 
significant role with respect to bioanalytical samples. 
Sample preparation is applied to remove the matrix of 
interfering biological compounds. It is essential to 
reduce the effect of the matrix formed due to biological 
and buffer components1. The liquid-liquid extraction 
procedure was used to extract telmisartan from plasma 
using ethanol as the extracting solvent. Samples were 
prepared by adding 10 µl of each working solution of 
TEL to 80 µl of blank plasma and vortexed for 1 minute. 
Then 10 µl of internal standard solution (IS) of 
pioglitazone (50 µg/ml) equivalent to 5 µg/ml in plasma 
was added to the plasma and vortexed for 1 minute. 
Then the sample was extracted with 1.5 ml ethanol. 
After the addition of extracting solvent, the sample was 
vortexed for 5 minutes and centrifuged at 3000 rpm for 
10 minutes. The organic layer was separated and 
evaporated at 40 ºC to dryness by using a gentle stream 
of nitrogen. The residue was reconstituted in 200 µL of 
the mobile phase and vortexed for 1 minute. Finally, the 
sample was filtered using a 0.45 µm syringe filter, and 
10 µL was injected into the HPLC system. 
 




Bioanalytical method validation: 
The developed HPLC conditions were validated as per 
the ICH guideline for bioanalytical method validation. 
The developed method was validated for its specificity 
and selectivity, the Limit of Detection (LOD) and Limit 
of Quantitation (LOQ), calibration and linearity, 
precision and accuracy as per the bioanalytical method 
validation guideline suggested by ICH. 
 
Specificity and Selectivity: 
These parameters were conducted on rat plasma after it 
was prepared for analysis by liquid-liquid extraction. 
The unspiked sample was run and analysed to determine 
if there is any interference by peaks coming from blank / 
non-spiked plasma sample at the retention time of TEL 
and IS. 
 
Limit of Detection (LOD) and Limit of Quantitation 
(LOQ): 
A calibration curve with five points at low concentration 
levels for TEL in plasma was drawn by plotting the peak 
area ratio (TEL: IS) against concentration 0.07, 0.1, 0.5, 
1 and 2 μg/ml. The linear regression equation was 
investigated along with its correlation coefficient for 
Beer’s Law agreement. From the curve, the LOD and 
LOQ in terms of the concentration of the TEL were 
estimated by calculation using the following equations. 
 
             3.3SD 
LOD = ––––––  (Eq 1) 
                S 
 
             10SD 
LOQ = ––––––  (Eq 2) 
                  S 
 
Where SD the standard deviation between area ratios of 
six replications of low concentration standard and S is 
the slope of the regression line. The obtained LOD and 
LOQ values were then prepared in plasma and injected 
into the system for six replicate measurements. The 
relative standard deviation (% RSD) for LOD and LOQ 
were calculated by the following equation. 
 
                 SD 
% RSD = ––– × 100%  (Eq 3) 
                 M 
 
Where SD is the standard deviation and M is the mean 
value of six replicate measurements. The acceptance 
criteria for LOD and LOQ is % RSD less than 33% and 
10%, respectively11. 
 
Calibration and Linearity: 
The seven points of calibration curve were constructed 
by plotting peak area ratio of TEL to the internal 
standard pioglitazone versus TEL concentration in 
plasma. Linearity was tested for TEL in the plasma 
concentrations of 0.07, 0.1, 0.5, 1, 2, 5, and 10µg/ml. 
The linearity of the method was determined by the 
estimation of the regression coefficient (R2) value. The 
desirable value of R2 should not be less than 0.99912. 
 
Precision and Accuracy: 
Precision and accuracy were determined by analyzing 
three replicates at three different concentration levels. 
The three quality control samples were LQC, MQC and 
HQC. The low QC (LQC) was 1.5µg/ml, mid QC 
(MQC) was 7.5µg/ml, and the high QC (HQC) was 15 
µg/ml. The samples for all quality control levels were 
prepared by the same method used for preparing the 
samples for linearity. All concentrations were spiked into 
plasma with internal standard and subjected to all the 
steps mentioned above of sample preparation. The 
concentration of quality control samples was calculated 
by using the linearity equation. The precision was 
expressed as % RSD between the accuracy values at 
each QC concentration levels. Accuracy was calculated 
using the following equation. 
 
                                               measured concentration 
Accuracy (% recovery) = –––––––––––––––––––× 100% 
                                             added concentration              (Eq 4) 
 
Pharmacokinetic study: 
The applicability of the developed HPLC method for 
TEL in rat plasma was demonstrated by the results 
obtained from pharmacokinetic studies conducted on 
three male Sprague-Dawley rats weighing 280 ± 20g and 
aged 9-10 weeks were purchased from Sapphire 
Enterprise, Selangor, Malaysia. Before the experiment, 
the rats had free access to normal food and water. The 
three rats were housed in one cage and acclimatized with 
laboratory environment for one week on a standard 12 
hours light/dark cycle at a room temperature of 25 ± 3ºC 
and relative humidity of 50 ± 10%. The rats were kept in 
fasting condition overnight (12 h) before the experiment 
was carried out, but the water access was allowed. The 
dose of telmisartan was 4mg/kg, which was administered 
through gastric gavage. Blood samples were collected at 
different time points after dosing. The study protocol 
was approved by Institutional Animal Care and Use 
Committee (IACUC-IIUM) in the meeting No. 2/2017 
on the 28 November 2017. The rats were anesthetized by 
pentobarbital intraperitoneal injection (50mg/kg, in 
volume 0.83ml/kg). 0.5ml of blood samples were 
collected from the retro-orbital vein of rat in EDTA 
tubes as an anticoagulant at 0.5, 1, 2, 4, 6 hours after 
dosing. They are mixed and immediately centrifuged at 
3000rpm for 10 minutes. The plasma was separated and 
stored at -80ºC until drug analysis was carried out using 
HPLC method. Pharmacokinetic parameters of TEL 
were calculated using non-compartmental methods. The 
maximum concentration (Cmax) and the time to reach the 
maximum concentration (Tmax) were obtained directly 
by visual inspection of the data from the plasma 
concentration versus time plot. Areas under the plasma-
concentration-time curve from time zero to the last 
measurable TEL sample time and to infinity (AUC0-t and 




AUC0-inf) were calculated by trapezoid rule. The 
elimination rate constant (Kel) was derived from the 
slope of the log plasma concentration versus time plot, 
and elimination half-life (T1/2) was calculated by formula 
T1/2 = 0.693/Kel (Nair et al., 2014) for the period of 0 to 6 
h. 
 
RESULTS AND DISCUSSION: 
Bioanalytical Method validation: 
HPLC method and extraction of drug from plasma: 
The developed HPLC method was very simple, 
involving an equal volume ratio of buffer and 
acetonitrile. Total chromatographic run time was 14 min. 
Plasma extraction method developed was a simple 
liquid-liquid extraction. TEL analysis in plasma sample 
was previously reported following liquid-liquid 
extraction involving dichloromethane as extracting 
organic solvent13. In this research, ethanol was used as 
an extracting solvent, but the quantity required of 
ethanol is very small, only 1.5ml per sample. 
 
Selectivity and Specificity: 
Specificity and selectivity were studied for the 
examination of the presence of interfering components14. 
The developed HPLC method was found to be selective 
and specific as it was able to differentiate and quantify 
TEL in the presence of other plasma component and the 
IS. IS was selected as internal standard because of its 
adequate resolution with TEL, satisfactory peak shapes, 
stability and consistency in area count during the 
analysis. During the validation process, no peaks were 
found at TEL and IS retention times in mobile phase and 
plasma as illustrated in Fig.1. The chromatogram of the 
same showed good separation with low background 
noise. The retention time for IS and TEL were about 7.5 
min and 12.0 min, respectively. The total 
chromatographic run time was 14.0 min. 
 
 
Fig 1. Typical HPLC chromatogram of a) blank mobile phase, b) blank rat plasma, c) pioglitazone (IS) (5µg/ml) spiked in rat plasma, d) 
telmisartan (5µg/ml) spiked in rat plasma, and e) telmisartan (5µg/ml) spiked in rat plasma with IS. 
 
 
Linearity and Range: 
The linearity of an analytical method is its ability to 
elicit that test results are proportional to the 
concentration of analyte in samples within a given range 
(15). Linearity was plotted over 7-points concentration 
ranges: 0.07, 0.1, 0.5, 1, 2, 5, and 10µg/ml for TEL in 
plasma. The Linear calibration curve (Fig. 2) with a 
correlation coefficient (R2) 0.9986 was obtained. The R2 
indicated an excellent linear correlation between peak 
area ratios (TEL to IS) and concentration of telmisartan. 
The linearity equation was y = 0.5908x + 0.0652. 
 
 
Figure 2: Linear calibration curve by HPLC method for TEL 
spiked plasma samples 




LOD and LOQ: 
The limit of detection (LOD) is the smallest 
concentration of the analyte that gives the measurable 
response while the limit of quantification (LOQ) is the 
smallest concentration of the analyte, which gives 
response that can be accurately quantified16. A five-
points of low concentrations of telmisartan in plasma 
ranges 0.07, 0.1, 0.5, 1, and 2µg/ml were plotted in area 
ratio of telmisartan to IS versus concentration of TEL 
which shows acceptable linearity in low concentration 
range (Fig. 3). The minimum detectable concentration of 
telmisartan (LOD) was found to be 0.025µg/ml, whereas 
the quantitative limit (LOQ) was 0.07µg/ml. 
Confirmation tests with LOD and LOQ showed 
acceptable values of % RSD (5.16% for LOD and 4.2% 
for LOQ) between area ratios of six concentrations each. 
Low detectable and quantifiable concentration indicate 
the sensitivity of the HPLC methods. One of the 
previously reported bioanalytical methods involving 
HPLC-UV detection for TEL in plasma sample resulted 
in LOQ of 1µg/ml17. In this research, 0.07µg/ml TEL 
concentration as LOQ is indicative of higher sensitivity 
compared to that reported methods. The high sensitive 
method is suitable enough to quantify low drug 
concentration in a pharmacokinetic study. 
 
 
Figure 3: Low concentration calibration curve of TEL in plasma 
(0.07 – 2 µg/ml) 
 
 
Precision and Accuracy: 
The accuracy of an analytical method describes the 
closeness of test results to the actual concentration of 
analytes. In contrast, the precision is a measure of the 
degree of repeatability and reproducibility of the 
analytical method18. In this research, only intra-day 
precision was evaluated as part of the partial method 
validation study. The accuracy and precision of the 
method were assessed by analysing the three Quality 
control (QC) samples (1.5 µg/ml LQC, 7.5 µg/ml MQC, 
and 15 µg/ml HQC). The blank plasma was spiked with 
these QC samples according to the procedure described 
in the methodology. Results are shown in Table 4. The 
accuracy of this bioanalytical method for all QC samples 
was ranged within 85.17% to 107.97 %. The acceptable 
limit for accuracy values in case of plasma sample was 
stated as 85 -115% whereas the acceptable precision 
value calculated as % RSD should be within ± 15%19,20. 
Therefore, the developed method was satisfactory in 
terms of accuracy and precision. Apart from the 
analyst’s skill, in bioanalytical methods, accuracy and 
precision depends mainly on the consistency of plasma 
extraction, tailing free peak shapes, consistency of the 
analytical system that is used in the study. The method 
employed in this research bears a simple and rapid 
liquid-liquid extraction with excellent recovery, sharp 
peak shapes and consistent performance of the HPLC 
system21. The mixed standard containing TEL and IS 
were injected before and after each set of analysis. The 
area ratios were compared between six consecutive 
injections, which was within 2% indicating consistent 
running of the chromatographic system. All of these 
factors contributed to the acceptable precision and 
accuracy values. Therefore, the accuracy and precision 
of the method evaluated at three quality control level met 
the acceptance criteria. This bioanalytical method was 
used in the pharmacokinetic studies to quantify the 
telmisartan in the plasma of rats. 
Table 4: Precision and accuracy of the bioanalytical method for telmisartan in rat plasma 
QC samples Added conc. Measured conc. Mean conc. SD Precision % RSD Accuracy % recovery 














































Pharmacokinetic Parameters:  
The established HPLC method was sensitive enough to 
assess the pharmacokinetic parameters following a 
single-dose of TEL in experimental rats. The mean 
plasma drug concentration-time profile of TEL is shown 
in Figure 4. The pharmacokinetic parameters values such 
as maximum plasma concentration (Cmax), time required 
for maximum plasma concentration (Tmax), area under 
the curve (plasma concentration) from the initial time to 
6 h (AUC 0-t), area under the curve (plasma 
concentration) from time zero to infinity (AUC0-∞), the 
elimination rate constant (Kel), and terminal half-life 
(t1/2) have been summarized in Table 5. 
 





Figure 4. In- vivo pharmacokinetic profile of TEL, Error bar 
represents SD (n=3). 
 
Table 5: Pharmacokinetic parameters of TEL after oral 
administration of TEL to rats. 
Parameters Mean ± SD (n=3) 
Cmax (µg/ml) 0.164 ± 0.016 
Tmax (h) 1 ± 0.000 
AUC0-t  (µg h/ml) 0.306 ± 0.080 
AUC0-∞ (µg h/ml) 0.333 ± 0.078 
Kel (h
-1) 0.448 ± 0.074 
T1/2 (h) 1.575 ± 0.256 
 
CONCLUSIONS: 
The HPLC method developed and validated was simple, 
rapid, specific, sensitive and reproducible for the 
quantification the TEL and studying the pharmacokinetic 
parameters in the rat model. 
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